Regeneron(REGN) Prnewswire·2025-02-24 10:45Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Regeneron Pharmaceuticals, Inc. regarding a class action lawsuit alleging misleading statements and omissions related to the pricing and sales of Eylea, a primary product of the company [1]. Allegations Summary - The lawsuit claims that Regeneron made materially false and misleading statements during the class period from November 2, 2023, to October 30, 2024 [1]. - Specific allegations include that Regeneron paid credit card fees to distributors to prevent them from charging higher prices to Eylea customers using credit cards, which effectively subsidized the prices for these customers [1]. - It is alleged that these actions led to a price concession that lowered Eylea's selling price, providing a competitive advantage in a sensitive pricing environment for retina practices [1]. - The complaint asserts that Regeneron misrepresented Eylea sales figures and overstated the Average Selling Price (ASP) reported to federal agencies, violating the False Claims Act [1]. Next Steps for Shareholders - Shareholders who purchased shares of Regeneron during the specified class period are encouraged to register for the class action by March 10, 2025, to potentially be appointed as lead plaintiffs [2]. - Registration will include enrollment in a portfolio monitoring software to provide updates throughout the case lifecycle [2]. Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].